AR015751A1 - Compuestos ligandos azabiciclicos de receptores 5ht1, compuestos para uso en la manufactura de un medicamento para modular la neurotransmisionserotonergica, composiciones farmaceuticas, procedimientos de tratamiento y compuestos utiles para la preparacion de dichos ligandos - Google Patents
Compuestos ligandos azabiciclicos de receptores 5ht1, compuestos para uso en la manufactura de un medicamento para modular la neurotransmisionserotonergica, composiciones farmaceuticas, procedimientos de tratamiento y compuestos utiles para la preparacion de dichos ligandosInfo
- Publication number
- AR015751A1 AR015751A1 ARP990101572A ARP990101572A AR015751A1 AR 015751 A1 AR015751 A1 AR 015751A1 AR P990101572 A ARP990101572 A AR P990101572A AR P990101572 A ARP990101572 A AR P990101572A AR 015751 A1 AR015751 A1 AR 015751A1
- Authority
- AR
- Argentina
- Prior art keywords
- ring
- branched
- compounds
- alkyl
- linear
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 4
- 239000003446 ligand Substances 0.000 title 1
- 239000007788 liquid Substances 0.000 title 1
- 238000004519 manufacturing process Methods 0.000 title 1
- 229940126601 medicinal product Drugs 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 5
- 125000001153 fluoro group Chemical group F* 0.000 abstract 3
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract 2
- 125000003118 aryl group Chemical group 0.000 abstract 2
- 229910052799 carbon Inorganic materials 0.000 abstract 2
- 125000005843 halogen group Chemical group 0.000 abstract 2
- 125000005842 heteroatom Chemical group 0.000 abstract 2
- 239000001257 hydrogen Substances 0.000 abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 abstract 2
- 125000004435 hydrogen atom Chemical class [H]* 0.000 abstract 2
- -1 hydroxy, amino Chemical group 0.000 abstract 2
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 2
- 125000004430 oxygen atom Chemical group O* 0.000 abstract 2
- 125000003373 pyrazinyl group Chemical group 0.000 abstract 2
- 125000003226 pyrazolyl group Chemical group 0.000 abstract 2
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 abstract 1
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 abstract 1
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 abstract 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 abstract 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 abstract 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 abstract 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 125000004849 alkoxymethyl group Chemical group 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 1
- 125000002619 bicyclic group Chemical group 0.000 abstract 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 abstract 1
- 229910052794 bromium Inorganic materials 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- 239000000460 chlorine Substances 0.000 abstract 1
- 229910052801 chlorine Inorganic materials 0.000 abstract 1
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 229910052731 fluorine Inorganic materials 0.000 abstract 1
- 239000011737 fluorine Substances 0.000 abstract 1
- 125000002541 furyl group Chemical group 0.000 abstract 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 1
- 125000004446 heteroarylalkyl group Chemical group 0.000 abstract 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 abstract 1
- 125000002883 imidazolyl group Chemical group 0.000 abstract 1
- 125000001041 indolyl group Chemical group 0.000 abstract 1
- 239000011630 iodine Substances 0.000 abstract 1
- 229910052740 iodine Inorganic materials 0.000 abstract 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 abstract 1
- 125000001786 isothiazolyl group Chemical group 0.000 abstract 1
- 125000000842 isoxazolyl group Chemical group 0.000 abstract 1
- 125000001624 naphthyl group Chemical group 0.000 abstract 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 abstract 1
- 125000002971 oxazolyl group Chemical group 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 239000001301 oxygen Substances 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 125000004076 pyridyl group Chemical group 0.000 abstract 1
- 125000000714 pyrimidinyl group Chemical group 0.000 abstract 1
- 125000000168 pyrrolyl group Chemical group 0.000 abstract 1
- 125000006413 ring segment Chemical group 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229920006395 saturated elastomer Polymers 0.000 abstract 1
- 239000011593 sulfur Substances 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
- 125000003831 tetrazolyl group Chemical group 0.000 abstract 1
- 125000000335 thiazolyl group Chemical group 0.000 abstract 1
- 125000001544 thienyl group Chemical group 0.000 abstract 1
- 125000001425 triazolyl group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Reproductive Health (AREA)
- Gynecology & Obstetrics (AREA)
- Hospice & Palliative Care (AREA)
- Addiction (AREA)
- Child & Adolescent Psychology (AREA)
- Psychology (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Luminescent Compositions (AREA)
Abstract
Un compuesto de la formula (I) en la que R3, R4 y Z se seleccionan independientemente, entre hidrogeno, halo (por ejemplo, cloro, fluor, bromo o yodo),alquilo C1-4 opcionalmente sustituido con 1-3 átomos de fluor, alcoxi C1-4 opcionalmente sustituidocon 1-3 átomos de fluor, y alcoxi C1-4-alquilo C1-4, dondecada uno de los radicales alquilo puede estar opcionalmente sustituido con 1-3 átomos de fluor; W es -CH2-O-alquilo C1-6 donde el radical alquilo puede serlineal o ramificado; o W es -CH2NR1R2, donde R1 y R2 se seleccionan independientemente entre hidrogeno y alquilo C1-6 lineal o ramificado; o R1 y R2, junto conel nitrogeno al que están unidos, forman un anillo monocíclico no aromático saturado o insaturado de 4-7 miembros o un anillo bicíclico de 7-10 miembros queopcionalmente puede contener 1 o 2 heteroátomos además del nitrogeno de NR1R2, donde dichos heteroátomos se seleccionan independientemente entre oxígeno,nitrogeno y azufre, y donde de 1-3 átomos de C del anillo, o uno delos átomos del anillo, pueden ser sustituidos opcional e independientemente con alquiloC1-4 lineal o ramificado, alcoxi C1-6 lineal o ramificado, alquil C1-3 lineal o ramificado -cicloalquilo C3-7, hidroxi, amino, ciano, halo, aril-alquilo C1-3linealo ramificado o heteroarilalquilo C1-3 lineal o ramificado, donde dicho arilo se selecciona entre fenilo y naftilo y dicho heteroarilo se seleccionaentre oxazolilo, isoxazolilo, tiazolilo, isotiazolilo, furanilo, pirazolilo, pirrolilo, tetrazolilo, triazolilo, tienilo, imidazolilo, pirazinilo, pirazolilo,indolilo, isoindolilo, pirazinilo, cinnolinilo, piridinilo y pirimidinilo; con la condicion de que en cualquier anillo formado por NR1R2: (a) no puede habermás de un átomo de oxígeno en el anillo; (b) no puede haber ningun radical hidroxi, alcoxi, alcoximetilo, ciano, amino o alquilamino unido directamente aningun átomo de nitrogeno; y (c) ningun carbono del anillo que esté unido mediante un doble enlace a otro carbono del anillo y no formaparte de un sistema deanillo aromático, puede estar unido a un átomo de oxígeno del anillo o a un átomo de nitrogeno del anillo; y las sales farmacéuticamente aceptables de tales
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US8123798P | 1998-04-09 | 1998-04-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR015751A1 true AR015751A1 (es) | 2001-05-16 |
Family
ID=22162936
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP990101572A AR015751A1 (es) | 1998-04-09 | 1999-04-07 | Compuestos ligandos azabiciclicos de receptores 5ht1, compuestos para uso en la manufactura de un medicamento para modular la neurotransmisionserotonergica, composiciones farmaceuticas, procedimientos de tratamiento y compuestos utiles para la preparacion de dichos ligandos |
Country Status (40)
| Country | Link |
|---|---|
| US (2) | US6525048B1 (es) |
| EP (1) | EP1070065B1 (es) |
| JP (1) | JP3496759B2 (es) |
| KR (1) | KR100378931B1 (es) |
| CN (1) | CN1117092C (es) |
| AP (1) | AP1175A (es) |
| AR (1) | AR015751A1 (es) |
| AT (1) | ATE248838T1 (es) |
| AU (1) | AU749254B2 (es) |
| BG (1) | BG104915A (es) |
| BR (1) | BR9909522A (es) |
| CA (1) | CA2327782A1 (es) |
| CO (1) | CO5080727A1 (es) |
| CZ (1) | CZ20003684A3 (es) |
| DE (1) | DE69910997T2 (es) |
| DK (1) | DK1070065T3 (es) |
| DZ (1) | DZ2756A1 (es) |
| EA (1) | EA003400B1 (es) |
| ES (1) | ES2204154T3 (es) |
| HR (1) | HRP20000653A2 (es) |
| HU (1) | HUP0102400A3 (es) |
| ID (1) | ID26086A (es) |
| IL (1) | IL138629A0 (es) |
| IS (1) | IS5641A (es) |
| MA (1) | MA26619A1 (es) |
| MY (1) | MY133390A (es) |
| NO (1) | NO20005004L (es) |
| NZ (1) | NZ507010A (es) |
| OA (1) | OA11496A (es) |
| PA (1) | PA8469101A1 (es) |
| PE (1) | PE20000413A1 (es) |
| PL (1) | PL343408A1 (es) |
| PT (1) | PT1070065E (es) |
| SK (1) | SK14782000A3 (es) |
| TN (1) | TNSN99056A1 (es) |
| TR (1) | TR200002932T2 (es) |
| TW (1) | TW555758B (es) |
| WO (1) | WO1999052907A1 (es) |
| YU (1) | YU59400A (es) |
| ZA (1) | ZA992596B (es) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6231833B1 (en) | 1999-08-05 | 2001-05-15 | Pfizer Inc | 2,7-substituted octahydro-1H-pyrido[1,2-A]pyrazine derivatives as ligands for serotonin receptors |
| UA62015C2 (en) | 1998-12-28 | 2003-12-15 | Pfizer Prod Inc | Benzoizoxazol derivatives, a pharmaceutical composition (variants) based thereon (variants) and a method for treatment (variants) |
| PL211402B1 (pl) | 1999-09-03 | 2012-05-31 | Apbi Holdings | Zastosowanie dapoksetyny do leczenia lub zwalczania przedwczesnej ejakulacji |
| GB2362826A (en) * | 2000-06-02 | 2001-12-05 | Lilly Co Eli | A pharmaceutical composition comprising a serotonin transport inhibitor and a serotonin recptor antagonist |
| WO2003065970A2 (en) * | 2001-02-20 | 2003-08-14 | Royal College Of Surgeons Ie | Treatment of fibromyalgia and related fatigue syndromes using pindolol |
| AP2005003390A0 (en) * | 2003-03-12 | 2005-09-30 | Pfizer Prod Inc | Pyridyloxymethyl and benzisoxazole azabicyclic derivatives. |
| WO2005082370A1 (en) * | 2004-01-29 | 2005-09-09 | Pfizer Products Inc. | Combinations of an atypical antipsychotic and an aminomethylpyridyloxymethyl/benzisoxazole azabicyclic derivatives for treating cns disorders |
| JP4559749B2 (ja) * | 2004-02-16 | 2010-10-13 | あすか製薬株式会社 | ピペラジニルピリジン誘導体 |
| AR049478A1 (es) | 2004-03-25 | 2006-08-09 | Solvay Pharm Bv | Un procedimiento para la preparacion de 3-amino-8-(1-piperazinil)-2h-1-benzopiran-2-ona. sales e hidratos y composiciones farmaceuticas. |
| AR048112A1 (es) | 2004-03-25 | 2006-03-29 | Solvay Pharm Bv | Derivados de 1-(2h-1-benzopiran-2-on-8-il)-piperazina para el tratamiento de dolor |
| BRPI0512567A (pt) * | 2004-06-22 | 2008-03-25 | Pfizer Prod Inc | compostos antagonistas de receptor de histamina-3 diazabicìclico e respectivas composições farmacêuticas |
| EP1792629A4 (en) | 2004-08-25 | 2010-08-25 | Takeda Pharmaceutical | MEANS FOR THE PREVENTION / TREATMENT OF STRESS-RELATED HARNINE INCONTINENCE AND PRECAUTIONARY METHOD FOR THIS |
| JP2008512441A (ja) * | 2004-09-10 | 2008-04-24 | ファイザー・プロダクツ・インク | ピリジルオキシメチル、及びベンズイソオキサゾール・アザビシクロ誘導体を使用する、認知障害の治療方法 |
| RU2417082C2 (ru) * | 2009-07-14 | 2011-04-27 | Учреждение Российской Академии Наук Институт Физиологически Активных Веществ Ран (Ифав Ран) | Средство для восстановления утраченной памяти в норме и патологии у пациентов всех возрастных групп на основе n, n'-замещенных 3, 7-диазабицикло[3.3.1]нонанов, фармацевтическая композиция на его основе и способ ее применения |
| WO2014078568A1 (en) | 2012-11-14 | 2014-05-22 | The Johns Hopkins University | Methods and compositions for treating schizophrenia |
| EP3870292A4 (en) | 2018-10-26 | 2022-11-09 | The Research Foundation for The State University of New York | COMBINATION OF SEROTONIN-SPECIFIC RESUPPUT INHIBITOR AND SEROTONIN 1A RECEPTOR PARTIAL AGONIST TO REDUCE L-DOPA-INDUCED DYSKINESIA |
| WO2020183011A1 (en) | 2019-03-14 | 2020-09-17 | Institut Curie | Htr1d inhibitors and uses thereof in the treatment of cancer |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5106849A (en) * | 1988-05-24 | 1992-04-21 | American Home Products Corporation | Use of aryl- and heteroaryl piperazinyl carboxamides in the treatment of various central nervous system disorders |
| MX19222A (es) * | 1989-01-23 | 1993-12-01 | Pfizer | Agentes ansioliticos bis-aza-biciclicos |
| US5157034A (en) * | 1991-02-27 | 1992-10-20 | Pfizer Inc. | Neuroleptic perhydro-1H-pyrido[1,2-a]pyrazines |
| CA2118936A1 (en) * | 1991-09-25 | 1993-04-01 | Gene M. Bright | Neuroleptic 2-substituted perhydro-1-h-pyrido[1,2-a]pyrazines |
| US5262428A (en) * | 1992-03-13 | 1993-11-16 | Wake Forest University | Biologically active tropane derivatives |
| ATE185565T1 (de) * | 1992-06-16 | 1999-10-15 | Pfizer | Verfahren und zwischenprodukte zur herstellung von bis-aza-bicyclischen anxiolytica |
| GB9410512D0 (en) * | 1994-05-25 | 1994-07-13 | Smithkline Beecham Plc | Novel treatment |
| US5731307A (en) * | 1994-09-30 | 1998-03-24 | Pfizer, Inc. | Neuroleptic 2,7-disubtituted perhydro-1h-pyrido 1, 2-A!pyrazines |
| US5614523A (en) * | 1995-01-17 | 1997-03-25 | Eli Lilly And Company | Compounds having effects on serotonin-related systems |
-
1999
- 1999-03-17 PA PA19998469101A patent/PA8469101A1/es unknown
- 1999-03-18 HR HR20000653A patent/HRP20000653A2/hr not_active Application Discontinuation
- 1999-03-18 HU HU0102400A patent/HUP0102400A3/hu unknown
- 1999-03-18 IL IL13862999A patent/IL138629A0/xx unknown
- 1999-03-18 KR KR10-2000-7011167A patent/KR100378931B1/ko not_active Expired - Fee Related
- 1999-03-18 WO PCT/IB1999/000457 patent/WO1999052907A1/en not_active Ceased
- 1999-03-18 DK DK99945686T patent/DK1070065T3/da active
- 1999-03-18 CZ CZ20003684A patent/CZ20003684A3/cs unknown
- 1999-03-18 AT AT99945686T patent/ATE248838T1/de not_active IP Right Cessation
- 1999-03-18 EP EP99945686A patent/EP1070065B1/en not_active Expired - Lifetime
- 1999-03-18 BR BR9909522-0A patent/BR9909522A/pt not_active Application Discontinuation
- 1999-03-18 ID IDW20002017A patent/ID26086A/id unknown
- 1999-03-18 US US09/403,892 patent/US6525048B1/en not_active Expired - Fee Related
- 1999-03-18 CA CA002327782A patent/CA2327782A1/en not_active Abandoned
- 1999-03-18 TR TR2000/02932T patent/TR200002932T2/xx unknown
- 1999-03-18 ES ES99945686T patent/ES2204154T3/es not_active Expired - Lifetime
- 1999-03-18 YU YU59400A patent/YU59400A/sh unknown
- 1999-03-18 JP JP2000543464A patent/JP3496759B2/ja not_active Expired - Fee Related
- 1999-03-18 CN CN99807195A patent/CN1117092C/zh not_active Expired - Fee Related
- 1999-03-18 SK SK1478-2000A patent/SK14782000A3/sk unknown
- 1999-03-18 PT PT99945686T patent/PT1070065E/pt unknown
- 1999-03-18 AU AU32687/99A patent/AU749254B2/en not_active Ceased
- 1999-03-18 DE DE69910997T patent/DE69910997T2/de not_active Expired - Fee Related
- 1999-03-18 EA EA200000910A patent/EA003400B1/ru not_active IP Right Cessation
- 1999-03-18 NZ NZ507010A patent/NZ507010A/en unknown
- 1999-03-18 PL PL99343408A patent/PL343408A1/xx not_active Application Discontinuation
- 1999-04-02 TW TW088105301A patent/TW555758B/zh not_active IP Right Cessation
- 1999-04-05 PE PE1999000270A patent/PE20000413A1/es not_active Application Discontinuation
- 1999-04-07 DZ DZ990057A patent/DZ2756A1/xx active
- 1999-04-07 TN TNTNSN99056A patent/TNSN99056A1/fr unknown
- 1999-04-07 MY MYPI99001344A patent/MY133390A/en unknown
- 1999-04-07 MA MA25527A patent/MA26619A1/fr unknown
- 1999-04-07 AR ARP990101572A patent/AR015751A1/es unknown
- 1999-04-08 ZA ZA9902596A patent/ZA992596B/xx unknown
- 1999-04-08 AP APAP/P/1999/001502A patent/AP1175A/en active
- 1999-04-09 CO CO99021093A patent/CO5080727A1/es unknown
-
2000
- 2000-09-26 IS IS5641A patent/IS5641A/is unknown
- 2000-10-04 NO NO20005004A patent/NO20005004L/no not_active Application Discontinuation
- 2000-10-06 OA OA1200000273A patent/OA11496A/en unknown
- 2000-11-07 BG BG104915A patent/BG104915A/xx unknown
-
2003
- 2003-02-11 US US10/364,804 patent/US6887905B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX9203249A (es) | Derivados del acido bencimidazolin-2-oxo-1-carboxilico y composiciones farmaceuticas que los contienen. | |
| ES539658A0 (es) | Procedimiento de preparacion de nuevos derivados de la xan- tina y de sus sales de adicion con acidos apropiados | |
| TW200716100A (en) | Aryl or heteroaryl fused imidazole compounds as anti-inflammatory and analgesic agents | |
| EA200500018A1 (ru) | Бензконденсированные гетероариламидные производные тиенопиридинов, применяемые в качестве терапевтических агентов, фармацевтические композиции, включающие их, и способы их применения | |
| ES2155535T3 (es) | Inhibidores de sintesis de apoliproteina b. | |
| ES2080815T3 (es) | Derivados de la 1-naftil-piperacina, sus procedimientos de preparacion y composiciones farmaceuticas que los contienen. | |
| AR128285A1 (es) | Formulaciones farmacéuticas y métodos para el tratamiento de trastornos metabólicos y hepáticos | |
| PE20212323A1 (es) | Formulaciones farmaceuticas | |
| MX9307946A (es) | Derivados de amina secundaria ciclica, un procedimiento para su preparacion, composiciones farmaceuticas que los contienen y su uso. | |
| CO2023002940A2 (es) | Derivados de espiropiperidinilo sustituidos con heteroarilo y usos farmacéuticos de los mismos | |
| CO5080727A1 (es) | Ligandos azabiciclicos de receptores 5 ht1 | |
| NO167803C (no) | Analogifremgangsmaate til fremstilling av terapeutiskordskilleaktive n-(4-piperidinyl)bicyklisk kondenserte 2-imidazolaminderivater. | |
| AR048717A1 (es) | Derivados de acido hexenoico, procedimientos para su preparacion, composiciones farmaceuticas que los comprenden y sus aplicaciones terapeuticas | |
| CO4950607A1 (es) | Inhibidores de la farnesil transferasa combinados con inhibidores de la hmg c o a reductasa para el tratamiento del cancer | |
| AR007937A1 (es) | Un compuesto derivado de bencimidazole, un procedimiento para prepararlo, un medicamento constituido por dicho compuesto y una composicion farmaceuticaque comprende dicho compuesto | |
| ES2069249T3 (es) | Derivados de imidazol, su procedimiento de preparacion y los compuestos farmaceuticos que los contienen. | |
| DK185984D0 (da) | Disubstituerede polymethyleniminer,fremgangsmaader til deres fremstilling og farmaceutiske kompositioner indeholdende dem | |
| CO4980875A1 (es) | Nuevos derivados de la equinocandina, su procedimiento de preparacion y su aplicacion como fungicidas | |
| AR125594A1 (es) | Moduladores alostéricos negativos novedosos de ciclopenta[c]pirrol de nr2b | |
| MX9200665A (es) | Derivados de ureas y tioureas disubstituidas, procedimiento para su preparacion y composiciones farmaceuticas que los contiene. | |
| AR058208A1 (es) | Derivados de indolizina,proceso de preparacion,composiciones farmaceuticas que los contienen y usos terapeuticos en alteraciones cardiovasculares. | |
| IT1214632B (it) | Glicin ammidi n-alchil(ene)-n-(0,0-disostituito-tiofosforil)- n',n'-disostituite, procedimento per la loro preparazione e acaricidi, insetticidi e fungicidi contenenti questi composti come ingrediente attivo. | |
| ES8307789A1 (es) | "un procedimiento para la preparacion de derivados de piridina y pirrolidina". | |
| MX9204220A (es) | Bencimidazoles. | |
| BR0002935A (pt) | Compostos tetrazolilalquil-indol como agentes antiinflamatórios e analgésicos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |